Advertisement

Treatment for Acute, Subacute and Chronic Low Back Pain

  • Ehab ShibanEmail author
  • Bernhard Meyer
Chapter

Abstract

Low back pain (LBP) has become the leading cause for living with disability in the world. In an analysis of two national surveys in the United States one third of U.S adult reported having LBP at least for 1 day during the last 3 months. In a national German survey 25% of women and 17% of men reported having LBP lasting for at least 3 months during the last year. LBP causes also a great financial burden to the health care system with high direct costs related to treatment as well as indirect costs due to sick leave or diminished productivity.

References (Including EBM Level)

  1. 1.
    Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Nicht-spezifischer Kreuzschmerz – Langfassung, 2. Auflage. Version 1. 2017.Google Scholar
  2. 2.
    Qaseem A, Wilt TJ, McLean RM, Forciea MA. Clinical Guidelines Committee of the American College of Physicians.Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166(7):514–30.CrossRefGoogle Scholar
  3. 3.
    GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602. (EBM=2C).Google Scholar
  4. 4.
    Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine (Phila Pa 1976). 2006;31(23):2724–7. (EBM 2B).CrossRefGoogle Scholar
  5. 5.
    Robert Koch Institut (RKI). Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI undDestatis. Berlin: RKI; 2015. http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtld/gesundheit_in_deutschland_2015.pdf. (EBM 2B).
  6. 6.
    Henschke N, Kuijpers T, Rubinstein SM, van Middelkoop M, Ostelo R, Verhagen A, Koes BW, van Tulder MW. Injection therapy and denervation procedures for chronic low- back pain: a systematic review. Eur Spine J. 2010;19(9):1425–49. (EBM=2A).CrossRefGoogle Scholar
  7. 7.
    Kamper SJ, Apeldoorn AT, Chiarotto A, Smeets RJ, Ostelo RW, Guzman J, van Tulder MW. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev. 2014;9:CD000963. (EBM=1A).Google Scholar
  8. 8.
    Linton SJ, Nordin E. A 5-year follow-up evaluation of the health and economic consequences of an early cognitive behavioral intervention for back pain: a randomized, controlled trial. Spine. 2006;31(8):853–8. (EBM=1B).CrossRefGoogle Scholar
  9. 9.
    Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225. (EBM=1A).CrossRefGoogle Scholar
  10. 10.
    Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2009;34(1):49–59. (EBM=1A).CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of NeurosurgeryKlinikum rechts der Isar, Technische Universität MünchenMunichGermany

Personalised recommendations